In utero exposure to antidepressants and the use of drugs for pulmonary diseases in children

European Journal of Clinical Pharmacology

Volumn 69, Issue 3, 2013, Pages 541-547

  Ter Horst, P G J ^a,b   Bos, H J ^b   De Jong Van De Berg, L T W ^b   Wilffert, B ^b  

^a Isala Klinieken ^*  (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Antidepressants; Asthma; In utero exposure; Teratogenicity

Indexed keywords

AMITRIPTYLINE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; INSULIN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; ASTHMA; CAUSAL ATTRIBUTION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; LUNG DISEASE; MATERNAL SMOKING; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DRUG PRESCRIPTIONS; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; LUNG DISEASES; MATERNAL EXPOSURE; NETHERLANDS; ODDS RATIO; PREGNANCY; PREGNANCY TRIMESTERS; PRENATAL EXPOSURE DELAYED EFFECTS; RESPIRATORY SYSTEM AGENTS; RISK ASSESSMENT; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 84877103103     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1314-6     Document Type: Article

References (40)

1. Andersson L, Sundstrom-Poromaa I, Wulff M, Astrom M, Bixo M (2004) Implications of antenatal depression and anxiety for obstetric outcome. Obstet Gynecol 104:467-476
2. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR (2004) Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 103:698-709
3. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation (2008). Obstet Gynecol 111:1001-1020
4. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5:e45
5. Alwan S, Reefhuis J, Rasmussen SA, Friedman JM (2011) Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol 51:264-270
6. Bakker MK, Kolling P, Van den Berg PB, De Walle HE, de Jong van den Berg LT (2008) Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 65:600-606
7. Briggs GG, Freeman RK, Yaffe SJ (2008) Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Williams & Wilkins, Baltimore
8. Kallen BA, Otterblad Olausson P (2007) Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 79:301-308
9. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, Berard A, Koren G (2007) Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther 29:918-926
10. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D (2007) First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 80:18-27
11. Cole JA, Ephross SA, Cosmatos IS, Walker AM (2007) Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16:1075-1085
12. Hallberg P, Odlind V, Sjoblom V (2006) Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. N Engl J Med 354:2188-2190
13. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA (2007) First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356:2675-2683
14. Alwan S, Reefhuis J, Botto LD, Rasmussen SA, Correa A, Friedman JM (2010) Maternal use of bupropion and risk for congenital heart defects. Obstet Gynecol 203:52-56
15. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH (2009) Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 339:b3569
16. Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, Livingston J, Boudreau DM, Smith DH, Davis RL, Willy ME, Platt R (2009) Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 18:246-252
17. Boucher N, Koren G, Beaulac-Baillargeon L (2009) Maternal use of venlafaxine near term: correlation between neonatal effects and plasma concentrations. Ther Drug Monit 31:404-409
18. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA (2006) Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354:579-587
19. Reefhuis J, Rasmussen SA, Friedman JM (2006) Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. N Engl J Med 354:2188-2190
20. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM (2007) Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356:2684-2692
21. Reis M, Kallen B (2010) Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med:1-11
22. Sadler TW, Langman J (2010) Langman's medical embryology. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, PA
23. Hilaire G, Duron B (1999) Maturation of the mammalian respiratory system. Physiol Rev 79:325-360
24. Azmitia EC (2001) Modern views on an ancient chemical: serotonin effects on cell proliferation, maturation, and apoptosis. Brain Res Bull 56:413-424
25. Mair KM, MacLean MR, Morecroft I, Dempsie Y, Palmer TM (2008) Novel interactions between the 5-HT transporter, 5-HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts. Br J Pharmacol 155:606-616
26. Fornaro E, Li D, Pan J, Belik J (2007) Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am J Respir Crit Care Med 176:1035-1040
27. Gunther S, Maroteaux L, Schwarzacher SW (2006) Endogenous 5-HT2B receptor activation regulates neonatal respiratory activity in vitro. J Neurobiol 66:949-961
28. Pan J, Copland I, Post M, Yeger H, Cutz E (2006) Mechanical stretch-induced serotonin release from pulmonary neuroendocrine cells: implications for lung development. Am J Physiol Lung Cell Mol Physiol 290:L185-L193
29. Phillippe M (1983) Fetal catecholamines. Obstet Gynecol 146:840-855
30. McDonald JV Jr, Gonzales LW, Ballard PL, Pitha J, Roberts JM (1986) Lung beta-adrenoreceptor blockade affects perinatal surfactant release but not lung water. J Appl Physiol 60:1727-1733
31. Hilaire G (2006) Endogenous noradrenaline affects the maturation and function of the respiratory network: possible implication for SIDS. Auton Neurosci 126-127:320-331
32. Viemari JC (2008) Noradrenergic modulation of the respiratory neural network. Respir Physiol Neurobiol 164:123-130
33. Schirm E, Tobi H, de Jong van den Berg LT (2004) Identifying parents in pharmacy data: a tool for the continuous monitoring of drug exposure to unborn children. J Clin Epidemiol 57:737-741
34. Bakker MK, Jentink J, Vroom F, Van den Berg PB, De Walle HE, de Jong van den Berg LT (2006) Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 113:559-568
35. Rothman KJ (2002) Epidemiology: an introduction. Oxford University Press, Oxford
36. Kozyrskyj AL, Mai XM, McGrath P, Hayglass KT, Becker AB, Macneil B (2008) Continued exposure to maternal distress in early life is associated with an increased risk of childhood asthma. Am J Respir Crit Care Med 177:142-147
37. Algert CS, Bowen JR, Lain SL, Allen HD, Vivian-Taylor JM, Roberts CL (2011) Pregnancy exposures and risk of childhood asthma admission in a population birth cohort. Pediatr Allergy Immunol
38. Bracken MB, Belanger K, Cookson WO, Triche E, Christiani DC, Leaderer BP (2002) Genetic and perinatal risk factors for asthma onset and severity: a review and theoretical analysis. Epidemiol Rev 24:176-189
39. Leonard S, Adler LE, Benhammou K, Berger R, Breese CR, Drebing C, Gault J, Lee MJ, Logel J, Olincy A, Ross RG, Stevens K, Sullivan B, Vianzon R, Virnich DE, Waldo M, Walton K, Freedman R (2001) Smoking and mental illness. Pharmacol Biochem Behav 70:561-570
40. Rocklin RE (2011) Asthma, asthma medications and their effects on maternal/fetal outcomes during pregnancy. Reprod Toxicol 32:189-197